Journey Medical Corp (DERM): who owns it and who trades it
As of Nov 16, 2026, no open-market insider purchases or sales of DERM were reported in the last 12 months. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Journey Medical
From the latest filingsOverall: about as much buying as selling. Funds and famous investors were close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns DERM
71 funds and institutions reported DERM shares worth $75.5M at the end of Q2 2026. The largest holder is Wasatch Advisors LP with $20.2M.
10 largest owners, by value
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Wasatch Advisors LP | 2.86M | – | $20.2M | +34% |
| Tang Capital Management LLC | 1.61M | – | $11.4M | No change |
| Vanguard Capital Management LLC | 675,185 | – | $4.8M | -38% |
| Punch & Associates Investment Management, Inc. | 536,000 | – | $3.8M | New |
| Pale Fire Capital SE | 528,584 | – | $3.7M | +10% |
| Opaleye Management Inc. | 350,000 | – | $2.5M | -64% |
| Summit Financial, LLC | 346,748 | – | $2.5M | -9% |
| Jane Street Group, LLC | 320,021 | – | $2.3M | New |
| Diametric Capital, LP | 295,663 | – | $2.1M | +51% |
| Ikarian Capital, LLC | 251,436 | – | $1.8M | No change |
| Renaissance Technologies LLC | 229,700 | – | $1.6M | -5% |
| Geode Capital Management, LLC | 216,004 | – | $1.5M | -53% |
| American Financial Group Inc | 180,000 | – | $1.3M | No change |
| Trexquant Investment LP | 171,338 | – | $1.2M | +510% |
| Marshall Wace, LLP | 139,843 | – | $990K | New |
| J. Goldman & Co LP | 137,584 | – | $974K | -72% |
| Millennium Management LLC | 110,016 | – | $779K | -71% |
| BlackRock, Inc. | 100,981 | – | $715K | -90% |
| XTX Topco Ltd | 100,923 | – | $715K | +244% |
| Vanguard Fiduciary Trust Co | 94,729 | – | $671K | -31% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
No DERM insider reported an open-market purchase or sale in the last 12 months.
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
DERM short interest
3.09M DERM shares are sold short. Over the last 12 reports the number of shares short went down 11%.
As of Oct 30, 2026, 3.09M DERM shares were sold short, up 3.2% from the report before. At the average daily volume of 204,724 shares, buying them all back would take about 15.1 trading days (days to cover).
Shares short
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 3.09M | – | +3% | 204,724 | 15.1 |
| Oct 15, 2026 | 2.99M | – | -2% | 180,196 | 16.6 |
| Sep 30, 2026 | 3.06M | – | +4% | 219,731 | 13.9 |
| Sep 15, 2026 | 2.93M | – | -1% | 130,023 | 22.5 |
| Aug 31, 2026 | 2.96M | – | +2% | 169,699 | 17.4 |
| Aug 14, 2026 | 2.92M | – | +1% | 280,041 | 10.4 |
| Jul 31, 2026 | 2.87M | – | -6% | 140,066 | 20.5 |
| Jul 15, 2026 | 3.05M | – | +2% | 160,958 | 19.0 |
| Jun 30, 2026 | 2.99M | – | -15% | 566,775 | 5.3 |
| Jun 15, 2026 | 3.52M | – | No change | 167,828 | 20.9 |
| May 29, 2026 | 3.51M | – | +1% | 247,363 | 14.2 |
| May 15, 2026 | 3.47M | – | -6% | 304,396 | 11.4 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Journey Medical company events
Journey Medical filed 5 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Aug 12, 2026.
- Aug 12, 2026ResultsReleased financial results. Filing
- Jun 26, 2026VoteReported shareholder vote results. Filing
- May 13, 2026ResultsReleased financial results. Filing
- Apr 21, 2026AnnouncementJourney Medical Corporation announced an expansion in pharmacy benefit coverage for Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release), the Company’s treatment for the inflammatory lesions of rosacea in adults. Filing
- Mar 25, 2026ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Journey Medical financials
Famous investors that hold DERM
3 of the 50 well-known investors we track reported holding DERM in their latest 13F filing. The largest position is Israel Englander's, worth $1.6M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 239,696 | $1.6M | 0.0% | +118% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 228,900 | $1.6M | 0.0% | -0% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 51,464 | $352K | 0.0% | -37% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named DERM in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Oct 9, 2026 | Wasatch Advisors LP | 13G/A | 11.0% |
| Oct 9, 2026 | Wasatch Advisors LP | 13G/A | 11.0% |
Questions about Journey Medical Corp (DERM) stock
Who owns the most DERM stock?
The largest reported owner of Journey Medical Corp (DERM) is Wasatch Advisors LP. In total, 71 funds and institutions reported holding DERM at the end of Q2 2026. See the largest owners.
Are DERM insiders buying or selling?
No DERM insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.
What is the short interest in DERM?
As of Oct 30, 2026, 3.09M DERM shares were sold short, up 3.2% from the report before. At the average daily volume of 204,724 shares, buying them all back would take about 15.1 trading days (days to cover). See the history.
Which famous investors hold DERM?
3 of the 50 well-known investors we track reported DERM in their latest 13F filing, including Israel Englander, Jim Simons, Ken Griffin. The largest position is worth $1.6M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.